Since founding BioCogniz, I have received numerous resumes from individuals expressing interest in positions and internships related to Drug Design, particularly Computer-Aided Drug Design (CADD).
Interestingly, a significant portion of these resumes assert expertise in drug design, despite lacking any substantive professional experience or publication record. Many applicants tout their proficiency in molecular docking tools acquired through various courses or resources.
However, it is essential to clarify what truly constitutes "Drug Design."
Furthermore, I am increasingly concerned when encountering statements such as, "I conducted some docking and discovered this drug."
It's imperative to recognize that docking a ligand with a protein does not equate to drug design. Similarly, merely downloading AI/ML code from platforms like Github/Gitlab and generating random SMILES does not qualify as 𝐀𝐈-𝐛𝐚𝐬𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐞𝐬𝐢𝐠𝐧.
These endeavors serve as tools and techniques aimed at facilitating comprehension of underlying processes, rather than constituting the essence of drug design itself.
If you're keen on delving deeper and participating in active research under my direct supervision, I invite you to join our upcoming 𝐋𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐌𝐚𝐬𝐭𝐞𝐫 𝐂𝐥𝐚𝐬𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐓𝐫𝐚𝐢𝐧𝐢𝐧𝐠. The batch is scheduled to commence on May 04, 2024, and slots are limited, so act swiftly!
For further information and registration, please reach out to us at 𝒊𝒏𝒇𝒐@𝒃𝒊𝒐𝒄𝒐𝒈𝒏𝒊𝒛.𝒄𝒐𝒎, with the subject line: "𝐋𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐌𝐚𝐬𝐭𝐞𝐫 𝐂𝐥𝐚𝐬𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐓𝐫𝐚𝐢𝐧𝐢𝐧𝐠 - 𝐌𝐚𝐲 𝐁𝐚𝐭𝐜𝐡."
Biochemistry || Bioinformatics || Nanotechnology || Bioremediation || computational biology || KNSG Scholar ’23
1wYou are a great work leader